Literature DB >> 28389701

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28389701     DOI： 10.1007/s00417-017-3669-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  8 in total

Review 1.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

2.  Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-11-25       Impact factor: 5.258

3.  Comments to: Ranibizumab for persistent diabetic macular edema after bevacizumab treatment.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Eur J Ophthalmol       Date:  2017-05-11       Impact factor: 2.597

4.  Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-06-04       Impact factor: 5.258

5.  Comments to: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Eur J Ophthalmol       Date:  2016-11-04       Impact factor: 2.597

6.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Bobak Bahrami; Thomas Hong; Meidong Zhu; Timothy E Schlub; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-25       Impact factor: 3.117

7.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258

8.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596
  8 in total
  3 in total

1.  Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-09       Impact factor: 3.117

2.  Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-20       Impact factor: 3.117

3.  Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.

Authors:  Rafael Campos Polo; Consuelo Rubio Sánchez; Diego Manuel García Guisado; María José Díaz Luque
Journal:  Clin Ophthalmol       Date:  2018-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.